What is Ray Therapeutics?
Ray Therapeutics is a biotechnology company focused on restoring vision in patients suffering from retinitis pigmentosa and other degenerative retinal diseases. The company is pioneering a novel optogenetics approach to address these challenging conditions. Its work in regenerative medicine and vision restoration places it at the forefront of ophthalmic innovation, aiming to provide transformative treatments for conditions with limited therapeutic options.
How much funding has Ray Therapeutics raised?
Ray Therapeutics has raised a total of $345M across 5 funding rounds:
Angel/Seed
$6M
Series A
$100M
Grant
$4M
Series A
$110M
Series B
$125M
Angel/Seed (2022): $6M with participation from 4BIO Capital
Series A (2023): $100M led by Novo Holdings, Norwest Venture Partners, 4BIO Capital, Deerfield, and Platanus Technology Pvt
Grant (2023): $4M supported by The California Institute for Regenerative Medicine
Series A (2025): $110M featuring TTM Capital, Foresite Capital, and OrbiMed
Series B (2026): $125M backed by 4BIO Capital, Marshall Wace, Norwest Venture Partners, Adage Capital Management, MSD, Novo Holdings, Franklin Templeton, Janus Henderson Group, Deerfield, and Invus
Key Investors in Ray Therapeutics
4BIO Capital
4BIO Capital is a London-based venture capital firm specializing in life sciences investments, focusing on advanced therapies that address significant unmet medical and social needs. Their investment strategy includes areas such as gene therapy, cell therapy, and RNA-based therapy.
Norwest Venture Partners
Founded in 1961, Norwest Venture Partners is a global, multi-stage venture capital and growth equity investment firm headquartered in Palo Alto, California. They invest across various sectors, including technology and healthcare.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, established in 1999. It is a leading investor in the life sciences sector, focusing on innovative healthcare and biotechnology.
What's next for Ray Therapeutics?
With its recent major strategic investment, Ray Therapeutics is poised for significant expansion. The substantial capital raised will likely fuel further clinical development, enhance manufacturing capabilities, and accelerate market entry. The company's focus on optogenetics suggests a commitment to cutting-edge scientific advancement, positioning it for continued growth and potential leadership in the vision restoration market. Future endeavors will likely involve navigating regulatory pathways and scaling production to meet patient needs.
See full Ray Therapeutics company page
